Safe use of proton pump inhibitors in patients with cirrhosis-Reference-Cited by-同舟云学术

Safe use of proton pump inhibitors in patients with cirrhosis

Published:2018-06-07 Issue:8 Volume:84 Page:1806-1820
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Weersink Rianne A.¹²^ORCID,Bouma Margriet³,Burger David M.⁴^ORCID,Drenth Joost P.H.⁵^ORCID,Harkes-Idzinga S. Froukje⁶,Hunfeld Nicole G.M.⁷⁸,Metselaar Herold J.⁹^ORCID,Monster-Simons Margje H.¹⁰¹¹,van Putten Sandra A.W.¹²,Taxis Katja²^ORCID,Borgsteede Sander D.¹⁷^ORCID

Affiliation:

1. Health Base Foundation; Houten The Netherlands

2. Department of Pharmacy, Unit of Pharmacotherapy, -Epidemiology & -Economics; University of Groningen; Groningen The Netherlands

3. Department of Guideline Development; Dutch College of General Practice; Utrecht The Netherlands

4. Department of Pharmacy; Radboud University Medical Center; Nijmegen The Netherlands

5. Department of Gastroenterology; Radboud University Medical Center; Nijmegen The Netherlands

6. Center for Information on Medicines; Royal Dutch Pharmacists Association (KNMP); The Hague The Netherlands

7. Department of Hospital Pharmacy; Erasmus University Medical Center; Rotterdam The Netherlands

8. Department of Intensive Care; Erasmus University Medical Center; Rotterdam The Netherlands

9. Department of Gastroenterology and Hepatology; Erasmus University Medical Center; Rotterdam The Netherlands

10. Dutch Medicines Evaluation Board; Utrecht The Netherlands

11. Department of Clinical Pharmacy and Pharmacology; University of Groningen; Groningen The Netherlands

12. De Brug Pharmacy; Almere The Netherlands

Funder

ZonMw

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.13615/fullpdf

Reference99 articles.

1. Overprescribing proton pump inhibitors;Forgacs;BMJ,2008

2. US Food and Drug Administration Safety information proton pump inhibitors [online] https://www.fda.gov/Drugs/DrugSafety/ucm199082.htm

3. Proton-pump inhibitors and risk of fractures: an update meta-analysis;Zhou;Osteoporosis Int,2016

4. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs;Laheij;JAMA,2004

5. Systematic review: hypomagnesaemia induced by proton pump inhibition;Hess;Aliment Pharmacol Ther,2012

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proton Pump Inhibitors in Patients with Cirrhosis: Pharmacokinetics, Benefits and Drawbacks;Current Gastroenterology Reports;2024-08-21

2. Review article: Oesophageal disorders in chronic liver disease;Alimentary Pharmacology & Therapeutics;2024-07-31

3. Recommendations for the safe use of direct oral anticoagulants in patients with cirrhosis based on a systematic review of pharmacokinetic, pharmacodynamic and safety data;European Journal of Clinical Pharmacology;2024-03-02

4. Leberzirrhosen;Therapie-Handbuch - Gastroenterologie und Hepatologie;2024

5. Effect of 90 Days Sub-chronic Administration of Omeprazole (A Proton Pump Inhibitor) on Haematological, Biochemical, Antioxidant, Reproductive and Histopathological Parameters in Male and Female Rats;Annals of Science and Technology;2023-12-01